A globally co-ordinated approach to sourcing that rewards non-pricing criteria is imperative to bolster the security of the off-patent industry’s supply chain in the wake of the coronavirus pandemic, James Burt tells Generics Bulletin in the second part of our exclusive interview.

In the first part of an exclusive two-part interview, James Burt – Accord’s executive vice-president for Europe, the Middle East and North Africa – talks to Generics Bulletin about the key actions taken by the generics industry to mitigate the coronavirus pandemic, and the changed landscape that the off-patent arena can expect to see in future.

Kodak’s new pharmaceutical unit receives a $765m loan from the US International Development Finance Corporation, through President Trump’s Defense Production Act, to produce critical pharma components that are essential but have lapsed into chronic national shortage, as defined by the FDA.

Changes to how the UK plans to implement the SPC manufacturing waiver after it separates itself fully from the EU following the current Brexit transition period have been criticized by the generics industry, while originators have welcomed the move.

Sandoz has announced joint plans with the Austrian government to invest over €150m in antibiotics manufacturing.

To ensure delivery of affordable healthcare to citizens, the Indian government’s department of pharmaceuticals has issued a notification highlighting the Production Linked Incentive Scheme that intends to boost domestic manufacturing of identified KSMs, intermediates and APIs by attracting large investments in the sector.